NMD4C Honored with Dr David Green Award for Excellence in Service Delivery at MDC Awards Gala
In April of 2024 we shared the exciting news that our network had been awarded one of the prestigious Dr David Green Awards from Muscular Dystrophy Canada (MDC), and last week Dr Jodi Warman-Chardon accepted the Dr David Green Excellence in Service Delivery Award on behalf of the network at the annual MDC Awards Gala.
Dr Warman-Chardon highlighted the many collaborative successes of the network to date, emphasizing our training and education initiatives that ensure the next generation of neuromuscular clinicians and researchers are well-prepared to meet the challenges of NMDs; and our patient partner training initiatives, developing online training modules to help patients take the first steps towards becoming trained patient partners, and researchers to become familiar with the research environment as it relates to patient engagement and take the first steps towards working with patient partners.
We are honored to receive the Excellence in Service Delivery Award for 2024 and are excited to continue working with MDC and the entire Canadian neuromuscular community towards our network mission to improve the care, research, and treatment of NMDs for all Canadians.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.